ANDREW D. CAMPBELL
- Type
- Physician · Allopathic & Osteopathic Physicians / Pediatrics / Pediatric Hematology-Oncology
- Where
- LANHAM, MD
- NPI
- 1770593303
- Received
- $100,509 in 119 records, 2019 to 2025 ($93,732 general, $6,777 research)
- As principal investigator
- $1,880,736 of research payments to others in 62 records
- Source
- CMS Open Payments search ↗
By year
| Program year | Kind | Records | Amount |
|---|---|---|---|
| 2025 | General payment | 15 | $4,079 |
| 2024 | General payment | 12 | $1,844 |
| 2023 | General payment | 41 | $32,946 |
| 2022 | General payment | 25 | $19,988 |
| 2022 | Research payment | 3 | $5,513 |
| 2021 | General payment | 9 | $13,296 |
| 2021 | Research payment | 1 | $1,264 |
| 2020 | General payment | 10 | $17,730 |
| 2019 | General payment | 3 | $3,847 |
By company
| Company | Records | Amount | Years |
|---|---|---|---|
| GLOBAL BLOOD THERAPEUTICS, INC. | 18 | $24,639 | 2020–2022 |
| Novartis Pharmaceuticals Corporation | 17 | $21,755 | 2019–2022 |
| VERTEX PHARMACEUTICALS INCORPORATED | 18 | $21,146 | 2022–2024 |
| Chiesi USA, Inc. | 17 | $18,613 | 2020–2023 |
| Agios Pharmaceuticals, Inc. | 36 | $8,863 | 2022–2025 |
| Omeros Corporation | 1 | $2,800 | 2020 |
| TerSera Therapeutics LLC | 1 | $1,110 | 2022 |
| Novo Nordisk Health Care AG | 1 | $655 | 2025 |
| PFIZER INC. | 6 | $618 | 2023–2025 |
| Novo Nordisk Inc | 2 | $246 | 2024–2025 |
| Genetix Biotherapeutics Inc | 2 | $61 | 2023 |
By nature of payment
| Nature | Records | Amount |
|---|---|---|
| Consulting Fee | 30 | $71,762 |
| Honoraria | 7 | $9,847 |
| Research payment | 4 | $6,777 |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a v | 6 | $5,330 |
| Food and Beverage | 60 | $4,256 |
| Travel and Lodging | 12 | $2,536 |
Records
| Date | Company | Amount | Nature | Form | Product | Study | Year |
|---|---|---|---|---|---|---|---|
| 2025-12-06 | Agios Pharmaceuticals, Inc. | $140 | Food and Beverage | In-kind items and services | PYRUKYND Drug, Genetically Defined Disease | 2025 | |
| 2025-12-06 | Novo Nordisk Inc | $121 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-12-05 | Agios Pharmaceuticals, Inc. | $16 | Food and Beverage | In-kind items and services | PYRUKYND Drug, Genetically Defined Disease | 2025 | |
| 2025-12-05 | Agios Pharmaceuticals, Inc. | $5 | Food and Beverage | In-kind items and services | PYRUKYND Drug, Genetically Defined Disease | 2025 | |
| 2025-10-24 | Novo Nordisk Health Care AG | $655 | Consulting Fee | Cash or cash equivalent | 2025 | ||
| 2025-10-04 | Agios Pharmaceuticals, Inc. | $49 | Food and Beverage | In-kind items and services | PYRUKYND Drug, Genetically Defined Disease | 2025 | |
| 2025-10-02 | Agios Pharmaceuticals, Inc. | $1 | Food and Beverage | In-kind items and services | PYRUKYND Drug, Genetically Defined Disease | 2025 | |
| 2025-10-01 | Agios Pharmaceuticals, Inc. | $147 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-10-01 | Agios Pharmaceuticals, Inc. | $147 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-07-31 | PFIZER INC. | $300 | Travel and Lodging | In-kind items and services | 2025 | ||
| 2025-07-31 | PFIZER INC. | $152 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-07-31 | PFIZER INC. | $50 | Travel and Lodging | In-kind items and services | 2025 | ||
| 2025-07-11 | Agios Pharmaceuticals, Inc. | $209 | Food and Beverage | In-kind items and services | PYRUKYND Drug, Genetically Defined Disease | 2025 | |
| 2025-05-13 | Agios Pharmaceuticals, Inc. | $139 | Food and Beverage | In-kind items and services | PYRUKYND Drug, Genetically Defined Disease | 2025 | |
| 2025-02-07 | Agios Pharmaceuticals, Inc. | $1,942 | Consulting Fee | Cash or cash equivalent | PYRUKYND Drug, Genetically Defined Disease | 2025 | |
| 2024-12-07 | Agios Pharmaceuticals, Inc. | $42 | Food and Beverage | In-kind items and services | PYRUKYND Drug, Genetically Defined Disease | 2024 | |
| 2024-12-07 | Agios Pharmaceuticals, Inc. | $5 | Food and Beverage | In-kind items and services | PYRUKYND Drug, Genetically Defined Disease | 2024 | |
| 2024-12-06 | Novo Nordisk Inc | $125 | Food and Beverage | In-kind items and services | 2024 | ||
| 2024-12-05 | Agios Pharmaceuticals, Inc. | $23 | Food and Beverage | In-kind items and services | PYRUKYND Drug, Genetically Defined Disease | 2024 | |
| 2024-10-02 | Agios Pharmaceuticals, Inc. | $6 | Food and Beverage | In-kind items and services | PYRUKYND Drug, Genetically Defined Disease | 2024 | |
| 2024-09-04 | VERTEX PHARMACEUTICALS INCORPORATED | $21 | Food and Beverage | In-kind items and services | CASGEVY Biological, SICKLE CELL DISEASE/BETA THALESSEMIA | 2024 | |
| 2024-07-23 | Agios Pharmaceuticals, Inc. | $14 | Travel and Lodging | Cash or cash equivalent | PYRUKYND Drug, Genetically Defined Disease | 2024 | |
| 2024-07-23 | Agios Pharmaceuticals, Inc. | $3 | Food and Beverage | In-kind items and services | PYRUKYND Drug, Genetically Defined Disease | 2024 | |
| 2024-06-07 | PFIZER INC. | $103 | Food and Beverage | In-kind items and services | OXBRYTA Drug, HEMATOLOGY | 2024 | |
| 2024-05-23 | Agios Pharmaceuticals, Inc. | $107 | Food and Beverage | In-kind items and services | PYRUKYND Drug, Genetically Defined Disease | 2024 | |
| 2024-04-11 | PFIZER INC. | $3 | Food and Beverage | In-kind items and services | OXBRYTA Drug, HEMATOLOGY | 2024 | |
| 2024-01-04 | Agios Pharmaceuticals, Inc. | $1,387 | Honoraria | Cash or cash equivalent | PYRUKYND Drug, Genetically Defined Disease | 2024 | |
| 2023-12-13 | VERTEX PHARMACEUTICALS INCORPORATED | $650 | Consulting Fee | Cash or cash equivalent | 2023 | ||
| 2023-12-07 | Agios Pharmaceuticals, Inc. | $164 | Food and Beverage | In-kind items and services | PYRUKYND Drug, Genetically Defined Disease | 2023 | |
| 2023-12-07 | Agios Pharmaceuticals, Inc. | $139 | Food and Beverage | In-kind items and services | PYRUKYND Drug, Genetically Defined Disease | 2023 | |
| 2023-12-06 | Genetix Biotherapeutics Inc | $22 | Food and Beverage | In-kind items and services | 2023 | ||
| 2023-10-28 | Agios Pharmaceuticals, Inc. | $11 | Food and Beverage | In-kind items and services | PYRUKYND Drug, Genetically Defined Disease | 2023 | |
| 2023-10-26 | Agios Pharmaceuticals, Inc. | $46 | Food and Beverage | In-kind items and services | PYRUKYND Drug, Genetically Defined Disease | 2023 | |
| 2023-10-25 | Agios Pharmaceuticals, Inc. | $60 | Food and Beverage | In-kind items and services | PYRUKYND Drug, Genetically Defined Disease | 2023 | |
| 2023-10-23 | Agios Pharmaceuticals, Inc. | $43 | Food and Beverage | In-kind items and services | PYRUKYND Drug, Genetically Defined Disease | 2023 | |
| 2023-08-28 | VERTEX PHARMACEUTICALS INCORPORATED | $6,825 | Consulting Fee | Cash or cash equivalent | 2023 | ||
| 2023-08-23 | VERTEX PHARMACEUTICALS INCORPORATED | $6,825 | Consulting Fee | Cash or cash equivalent | 2023 | ||
| 2023-08-03 | Chiesi USA, Inc. | $1,740 | Consulting Fee | Cash or cash equivalent | FERRIPROX Drug, TREAT IRON OVERLOAD FROM THALASSEMIA, SICKLE CELL OR ANOTHER ANEMIA | 2023 | |
| 2023-07-31 | VERTEX PHARMACEUTICALS INCORPORATED | $36 | Food and Beverage | In-kind items and services | 2023 | ||
| 2023-07-30 | VERTEX PHARMACEUTICALS INCORPORATED | $288 | Travel and Lodging | In-kind items and services | 2023 | ||
| 2023-07-27 | Chiesi USA, Inc. | $870 | Consulting Fee | Cash or cash equivalent | FERRIPROX Drug, TREAT IRON OVERLOAD FROM THALASSEMIA, SICKLE CELL OR ANOTHER ANEMIA | 2023 | |
| 2023-07-26 | Chiesi USA, Inc. | $870 | Consulting Fee | Cash or cash equivalent | FERRIPROX Drug, TREAT IRON OVERLOAD FROM THALASSEMIA, SICKLE CELL OR ANOTHER ANEMIA | 2023 | |
| 2023-07-13 | VERTEX PHARMACEUTICALS INCORPORATED | $336 | Travel and Lodging | In-kind items and services | 2023 | ||
| 2023-07-13 | VERTEX PHARMACEUTICALS INCORPORATED | $64 | Food and Beverage | In-kind items and services | 2023 | ||
| 2023-07-13 | VERTEX PHARMACEUTICALS INCORPORATED | $44 | Food and Beverage | In-kind items and services | 2023 | ||
| 2023-07-13 | VERTEX PHARMACEUTICALS INCORPORATED | $26 | Food and Beverage | In-kind items and services | 2023 | ||
| 2023-07-13 | VERTEX PHARMACEUTICALS INCORPORATED | $26 | Food and Beverage | In-kind items and services | 2023 | ||
| 2023-07-12 | VERTEX PHARMACEUTICALS INCORPORATED | $397 | Travel and Lodging | In-kind items and services | 2023 | ||
| 2023-07-12 | VERTEX PHARMACEUTICALS INCORPORATED | $141 | Food and Beverage | In-kind items and services | 2023 | ||
| 2023-06-17 | Agios Pharmaceuticals, Inc. | $31 | Food and Beverage | In-kind items and services | PYRUKYND Drug, Genetically Defined Disease | 2023 | |
| 2023-05-18 | Agios Pharmaceuticals, Inc. | $65 | Food and Beverage | In-kind items and services | PYRUKYND Drug, Genetically Defined Disease | 2023 | |
| 2023-05-15 | Chiesi USA, Inc. | $870 | Consulting Fee | Cash or cash equivalent | FERRIPROX Drug, TREAT IRON OVERLOAD FROM THALASSEMIA, SICKLE CELL OR ANOTHER ANEMIA | 2023 | |
| 2023-05-15 | Chiesi USA, Inc. | $870 | Consulting Fee | Cash or cash equivalent | FERRIPROX Drug, TREAT IRON OVERLOAD FROM THALASSEMIA, SICKLE CELL OR ANOTHER ANEMIA | 2023 | |
| 2023-05-14 | Chiesi USA, Inc. | $870 | Consulting Fee | Cash or cash equivalent | FERRIPROX Drug, TREAT IRON OVERLOAD FROM THALASSEMIA, SICKLE CELL OR ANOTHER ANEMIA | 2023 | |
| 2023-05-11 | Chiesi USA, Inc. | $870 | Consulting Fee | Cash or cash equivalent | FERRIPROX Drug, TREAT IRON OVERLOAD FROM THALASSEMIA, SICKLE CELL OR ANOTHER ANEMIA | 2023 | |
| 2023-05-10 | Chiesi USA, Inc. | $870 | Consulting Fee | Cash or cash equivalent | FERRIPROX Drug, TREAT IRON OVERLOAD FROM THALASSEMIA, SICKLE CELL OR ANOTHER ANEMIA | 2023 | |
| 2023-05-10 | PFIZER INC. | $7 | Food and Beverage | In-kind items and services | OXBRYTA Drug, HEMATOLOGY | 2023 | |
| 2023-04-12 | Genetix Biotherapeutics Inc | $38 | Food and Beverage | In-kind items and services | Zynteglo Drug, beta-thalassemia | 2023 | |
| 2023-02-15 | Agios Pharmaceuticals, Inc. | $114 | Food and Beverage | In-kind items and services | PYRUKYND Drug, Genetically Defined Disease | 2023 | |
| 2023-01-29 | Chiesi USA, Inc. | $7,500 | Consulting Fee | Cash or cash equivalent | FERRIPROX Drug, TREAT IRON OVERLOAD FROM THALASSEMIA, SICKLE CELL OR ANOTHER ANEMIA | 2023 | |
| 2023-01-29 | Chiesi USA, Inc. | $156 | Food and Beverage | Cash or cash equivalent | FERRIPROX Drug, TREAT IRON OVERLOAD FROM THALASSEMIA, SICKLE CELL OR ANOTHER ANEMIA | 2023 | |
| 2023-01-29 | Chiesi USA, Inc. | $84 | Travel and Lodging | Cash or cash equivalent | FERRIPROX Drug, TREAT IRON OVERLOAD FROM THALASSEMIA, SICKLE CELL OR ANOTHER ANEMIA | 2023 | |
| 2023-01-29 | Chiesi USA, Inc. | $45 | Travel and Lodging | Cash or cash equivalent | FERRIPROX Drug, TREAT IRON OVERLOAD FROM THALASSEMIA, SICKLE CELL OR ANOTHER ANEMIA | 2023 | |
| 2023-01-28 | Chiesi USA, Inc. | $509 | Travel and Lodging | Cash or cash equivalent | FERRIPROX Drug, TREAT IRON OVERLOAD FROM THALASSEMIA, SICKLE CELL OR ANOTHER ANEMIA | 2023 | |
| 2023-01-28 | Chiesi USA, Inc. | $213 | Travel and Lodging | Cash or cash equivalent | FERRIPROX Drug, TREAT IRON OVERLOAD FROM THALASSEMIA, SICKLE CELL OR ANOTHER ANEMIA | 2023 | |
| 2023-01-28 | Chiesi USA, Inc. | $101 | Food and Beverage | Cash or cash equivalent | FERRIPROX Drug, TREAT IRON OVERLOAD FROM THALASSEMIA, SICKLE CELL OR ANOTHER ANEMIA | 2023 | |
| 2023-01-28 | Chiesi USA, Inc. | $71 | Travel and Lodging | Cash or cash equivalent | FERRIPROX Drug, TREAT IRON OVERLOAD FROM THALASSEMIA, SICKLE CELL OR ANOTHER ANEMIA | 2023 | |
| 2023-01-18 | VERTEX PHARMACEUTICALS INCORPORATED | $24 | Food and Beverage | In-kind items and services | 2023 | ||
| 2022-12-13 | Agios Pharmaceuticals, Inc. | $832 | Honoraria | Cash or cash equivalent | PYRUKYND Drug, Genetically Defined Disease | 2022 | |
| 2022-12-12 | Agios Pharmaceuticals, Inc. | $89 | Food and Beverage | In-kind items and services | PYRUKYND Drug, Genetically Defined Disease | 2022 | |
| 2022-12-08 | Agios Pharmaceuticals, Inc. | $80 | Food and Beverage | In-kind items and services | PYRUKYND Drug, Genetically Defined Disease | 2022 | |
| 2022-10-21 | Agios Pharmaceuticals, Inc. | $35 | Food and Beverage | In-kind items and services | PYRUKYND Drug, Genetically Defined Disease | 2022 | |
| 2022-10-20 | TerSera Therapeutics LLC | $1,110 | Consulting Fee | Cash or cash equivalent | Quzyttir Drug, Acute Care | 2022 | |
| 2022-10-18 | Agios Pharmaceuticals, Inc. | $147 | Food and Beverage | In-kind items and services | PYRUKYND Drug, Genetically Defined Disease | 2022 | |
| 2022-10-12 | GLOBAL BLOOD THERAPEUTICS, INC. | $100 | Food and Beverage | In-kind items and services | OXBRYTA Drug, Sickle Cell Disease | 2022 | |
| 2022-09-07 | VERTEX PHARMACEUTICALS INCORPORATED | $5,335 | Consulting Fee | Cash or cash equivalent | 2022 | ||
| 2022-08-20 | Novartis Pharmaceuticals Corporation | $3,450 | Research payment | In-kind items and services | ADAKVEO Biological, HEMATOLOGY | PUBLICATION SUPPORT PROVIDED IN CONNECTION WITH HEOR RESEARCH | 2022 |
| 2022-08-03 | Agios Pharmaceuticals, Inc. | $142 | Food and Beverage | In-kind items and services | PYRUKYND Drug, Genetically Defined Disease | 2022 | |
| 2022-08-03 | Agios Pharmaceuticals, Inc. | $24 | Food and Beverage | In-kind items and services | PYRUKYND Drug, Genetically Defined Disease | 2022 | |
| 2022-07-15 | VERTEX PHARMACEUTICALS INCORPORATED | $29 | Food and Beverage | In-kind items and services | 2022 | ||
| 2022-07-15 | VERTEX PHARMACEUTICALS INCORPORATED | $28 | Food and Beverage | In-kind items and services | 2022 | ||
| 2022-06-11 | VERTEX PHARMACEUTICALS INCORPORATED | $46 | Food and Beverage | In-kind items and services | 2022 | ||
| 2022-06-10 | GLOBAL BLOOD THERAPEUTICS, INC. | $68 | Food and Beverage | In-kind items and services | OXBRYTA Drug, Sickle Cell Disease | 2022 | |
| 2022-05-16 | Agios Pharmaceuticals, Inc. | $1,942 | Honoraria | Cash or cash equivalent | PYRUKYND Drug, Genetically Defined Disease | 2022 | |
| 2022-05-02 | Novartis Pharmaceuticals Corporation | $1,475 | Research payment | In-kind items and services | ADAKVEO Biological, HEMATOLOGY | PUBLICATION SUPPORT PROVIDED IN CONNECTION WITH HEOR RESEARCH | 2022 |
| 2022-04-06 | Agios Pharmaceuticals, Inc. | $500 | Honoraria | Cash or cash equivalent | PYRUKYND Drug, Genetically Defined Disease | 2022 | |
| 2022-03-31 | Novartis Pharmaceuticals Corporation | $350 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | ADAKVEO Biological, HEMATOLOGY | 2022 | |
| 2022-03-31 | Novartis Pharmaceuticals Corporation | $223 | Travel and Lodging | In-kind items and services | ADAKVEO Biological, HEMATOLOGY | 2022 | |
| 2022-03-31 | Novartis Pharmaceuticals Corporation | $12 | Food and Beverage | In-kind items and services | ADAKVEO Biological, HEMATOLOGY | 2022 | |
| 2022-03-30 | GLOBAL BLOOD THERAPEUTICS, INC. | $2,915 | Consulting Fee | Cash or cash equivalent | OXBRYTA Drug, Sickle Cell Disease | 2022 | |
| 2022-03-30 | GLOBAL BLOOD THERAPEUTICS, INC. | $2,915 | Consulting Fee | Cash or cash equivalent | OXBRYTA Drug, Sickle Cell Disease | 2022 | |
| 2022-03-16 | Novartis Pharmaceuticals Corporation | $64 | Food and Beverage | In-kind items and services | ADAKVEO Biological, HEMATOLOGY | 2022 | |
| 2022-03-08 | Novartis Pharmaceuticals Corporation | $610 | Consulting Fee | Cash or cash equivalent | ADAKVEO Biological, HEMATOLOGY | 2022 | |
| 2022-03-02 | GLOBAL BLOOD THERAPEUTICS, INC. | $1,855 | Honoraria | Cash or cash equivalent | OXBRYTA Drug, Sickle Cell Disease | 2022 | |
| 2022-02-11 | GLOBAL BLOOD THERAPEUTICS, INC. | $530 | Honoraria | Cash or cash equivalent | OXBRYTA Drug, Sickle Cell Disease | 2022 | |
| 2022-01-13 | Novartis Pharmaceuticals Corporation | $588 | Research payment | In-kind items and services | ADAKVEO Drug, HEMATOLOGY | PUBLICATION SUPPORT PROVIDED IN CONNECTION WITH HEOR RESEARCH | 2022 |
| 2021-12-15 | GLOBAL BLOOD THERAPEUTICS, INC. | $1,060 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2021 | ||
| 2021-12-12 | GLOBAL BLOOD THERAPEUTICS, INC. | $81 | Food and Beverage | In-kind items and services | OXBRYTA Drug, SICKLE CELL DISEASE | 2021 | |
| 2021-12-10 | Novartis Pharmaceuticals Corporation | $2,440 | Consulting Fee | Cash or cash equivalent | ADAKVEO Biological, HEMATOLOGY | 2021 | |
| 2021-12-10 | Novartis Pharmaceuticals Corporation | $111 | Food and Beverage | In-kind items and services | ADAKVEO Biological, HEMATOLOGY | 2021 | |
| 2021-09-30 | GLOBAL BLOOD THERAPEUTICS, INC. | $3,180 | Consulting Fee | Cash or cash equivalent | OXBRYTA Drug, SICKLE CELL DISEASE | 2021 | |
| 2021-09-01 | GLOBAL BLOOD THERAPEUTICS, INC. | $1,855 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2021 | ||
| 2021-08-03 | Novartis Pharmaceuticals Corporation | $1,264 | Research payment | In-kind items and services | ADAKVEO Biological, HEMATOLOGY | PUBLICATION SUPPORT PROVIDED IN CONNECTION WITH HEOR ADAKVEO RESEARCH | 2021 |
| 2021-06-30 | GLOBAL BLOOD THERAPEUTICS, INC. | $3,710 | Consulting Fee | Cash or cash equivalent | OXBRYTA Drug, SICKLE CELL DISEASE | 2021 | |
| 2021-05-25 | GLOBAL BLOOD THERAPEUTICS, INC. | $64 | Food and Beverage | In-kind items and services | OXBRYTA Drug, SICKLE CELL DISEASE | 2021 | |
| 2021-02-17 | GLOBAL BLOOD THERAPEUTICS, INC. | $795 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2021 | ||
| 2020-12-17 | Omeros Corporation | $2,800 | Honoraria | Cash or cash equivalent | Narsoplimab Drug, Hematology Oncology | 2020 | |
| 2020-12-10 | Novartis Pharmaceuticals Corporation | $2,440 | Consulting Fee | Cash or cash equivalent | ADAKVEO Biological, HEMATOLOGY | 2020 | |
| 2020-12-08 | Chiesi USA, Inc. | $2,100 | Consulting Fee | Cash or cash equivalent | FERRIPROX Drug, TRANSFUSIONAL IRON OVERLOAD DUE TO THALASSEMIA SYNDROMES | 2020 | |
| 2020-11-24 | GLOBAL BLOOD THERAPEUTICS, INC. | $1,325 | Consulting Fee | Cash or cash equivalent | OXBRYTA Drug, SICKLE CELL DISEASE | 2020 | |
| 2020-11-24 | GLOBAL BLOOD THERAPEUTICS, INC. | $795 | Consulting Fee | Cash or cash equivalent | OXBRYTA Drug, SICKLE CELL DISEASE | 2020 | |
| 2020-09-24 | Novartis Pharmaceuticals Corporation | $1,220 | Consulting Fee | Cash or cash equivalent | ADAKVEO Biological, HEMATOLOGY | 2020 | |
| 2020-09-16 | GLOBAL BLOOD THERAPEUTICS, INC. | $2,120 | Consulting Fee | Cash or cash equivalent | OXBRYTA Drug, SICKLE CELL DISEASE | 2020 | |
| 2020-09-15 | GLOBAL BLOOD THERAPEUTICS, INC. | $635 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | OXBRYTA Drug, SICKLE CELL DISEASE | 2020 | |
| 2020-08-04 | Novartis Pharmaceuticals Corporation | $3,660 | Consulting Fee | Cash or cash equivalent | 2020 | ||
| 2020-05-28 | GLOBAL BLOOD THERAPEUTICS, INC. | $635 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | OXBRYTA Drug, SICKLE CELL DISEASE | 2020 | |
| 2019-12-05 | Novartis Pharmaceuticals Corporation | $3,660 | Consulting Fee | Cash or cash equivalent | ADAKVEO Biological, HEMATOLOGY | 2019 | |
| 2019-12-05 | Novartis Pharmaceuticals Corporation | $116 | Food and Beverage | In-kind items and services | ADAKVEO Biological, HEMATOLOGY | 2019 | |
| 2019-12-05 | Novartis Pharmaceuticals Corporation | $70 | Food and Beverage | In-kind items and services | ADAKVEO Biological, HEMATOLOGY | 2019 |
Research payments naming this person as principal investigator
| Date | Company | Paid to | Amount | Study | Year |
|---|---|---|---|---|---|
| 2025-11-13 | Novo Nordisk AS | CHILDRENS RESEARCH INSTITUTE | $986 | 4202-HEM-301 | 2025 |
| 2025-10-01 | Novartis Pharmaceuticals Corporation | CHILDRENS NATIONAL MEDICAL CENTER | $201 | A Phase III, Multicenter, Randomized, Placebo Controlled, Double-blind Study to Assess Efficacy and Safety of Crizanlizu | 2025 |
| 2025-09-25 | Novartis Pharmaceuticals Corporation | Childrens Hospital | $18,375 | A phase 2 Multicenter Open Label Study to Assess Appropriate Dosing and to Evaluate Safety of Crizanlizumab with or with | 2025 |
| 2025-08-21 | Novartis Pharmaceuticals Corporation | Childrens Hospital | $37,591 | An Open-label, Multi-center, Phase IV, Rollover Study for Patients With Sickle Cell Disease Who Have Completed a Prior N | 2025 |
| 2025-07-18 | GLOBAL BLOOD THERAPEUTICS, INC. | CHILDRENS RESEARCH INSTITUTE | $1,935 | AN OPENLABEL EXTENSION STUDY TO EVALUATE THE LONGTERM SAFETY OF GBT021601 ADMINISTERED TO PARTICIPANTS WITH SICKLE CELL | 2025 |
| 2025-07-18 | GLOBAL BLOOD THERAPEUTICS, INC. | CHILDRENS RESEARCH INSTITUTE | $14,832 | AN OPENLABEL EXTENSION STUDY TO EVALUATE THE LONGTERM SAFETY OF GBT021601 ADMINISTERED TO PARTICIPANTS WITH SICKLE CELL | 2025 |
| 2025-07-18 | GLOBAL BLOOD THERAPEUTICS, INC. | CHILDRENS RESEARCH INSTITUTE | $1,883 | AN OPENLABEL EXTENSION STUDY TO EVALUATE THE LONGTERM SAFETY OF GBT021601 ADMINISTERED TO PARTICIPANTS WITH SICKLE CELL | 2025 |
| 2025-07-18 | GLOBAL BLOOD THERAPEUTICS, INC. | CHILDRENS RESEARCH INSTITUTE | $4,515 | AN OPENLABEL EXTENSION STUDY TO EVALUATE THE LONGTERM SAFETY OF GBT021601 ADMINISTERED TO PARTICIPANTS WITH SICKLE CELL | 2025 |
| 2025-06-05 | GLOBAL BLOOD THERAPEUTICS, INC. | CHILDRENS RESEARCH INSTITUTE | $1,816 | AN OPENLABEL EXTENSION STUDY TO EVALUATE THE LONGTERM SAFETY OF GBT021601 ADMINISTERED TO PARTICIPANTS WITH SICKLE CELL | 2025 |
| 2025-06-05 | GLOBAL BLOOD THERAPEUTICS, INC. | CHILDRENS RESEARCH INSTITUTE | $1,935 | AN OPENLABEL EXTENSION STUDY TO EVALUATE THE LONGTERM SAFETY OF GBT021601 ADMINISTERED TO PARTICIPANTS WITH SICKLE CELL | 2025 |
| 2025-06-05 | GLOBAL BLOOD THERAPEUTICS, INC. | CHILDRENS RESEARCH INSTITUTE | $5,575 | AN OPENLABEL EXTENSION STUDY TO EVALUATE THE LONGTERM SAFETY OF GBT021601 ADMINISTERED TO PARTICIPANTS WITH SICKLE CELL | 2025 |
| 2025-04-16 | PFIZER INC. | CHILDRENS NATIONAL MEDICAL CENTER | $2,895 | AN OPENLABEL EXTENSION STUDY OF VOXELOTOR ADMINISTERED ORALLY TO PARTICIPANTS WITH SICKLE CELL DISEASE WHO HAVE PARTICIP | 2025 |
| 2025-03-01 | Novartis Pharmaceuticals Corporation | Childrens Hospital | $9,882 | A Phase III, Multicenter, Randomized, Placebo Controlled, Double-blind Study to Assess Efficacy and Safety of Crizanlizu | 2025 |
| 2025-01-17 | Novartis Pharmaceuticals Corporation | Childrens Hospital | $3,750 | A phase 2 Multicenter Open Label Study to Assess Appropriate Dosing and to Evaluate Safety of Crizanlizumab with or with | 2025 |
| 2025-01-14 | Novartis Pharmaceuticals Corporation | Childrens Hospital | $127,704 | An Open-label, Multi-center, Phase IV, Rollover Study for Patients With Sickle Cell Disease Who Have Completed a Prior N | 2025 |
| 2024-12-02 | ARENA PHARMACEUTICALS, INC. | Childrens National Medical Center Hematology and Oncology | $4,438 | A PHASE 23 RANDOMIZED MULTICENTER STUDY OF GBT021601 ADMINISTERED ORALLY TO PARTICIPANTS WITH SICKLE CELL DISEASE AND AN | 2024 |
| 2024-10-17 | Novo Nordisk AS | CHILDRENS RESEARCH INSTITUTE | $3,951 | 4202-HEM-301 | 2024 |
| 2024-10-16 | ARENA PHARMACEUTICALS, INC. | Childrens National Medical Center Hematology and Oncology | $18,594 | A PHASE 23 RANDOMIZED MULTICENTER STUDY OF GBT021601 ADMINISTERED ORALLY TO PARTICIPANTS WITH SICKLE CELL DISEASE AND AN | 2024 |
| 2024-09-11 | GLOBAL BLOOD THERAPEUTICS, INC. | Childrens Reasearch Institute | $4,750 | A PHASE 2A OPENLABEL SINGLE AND MULTIPLE DOSE STUDY TO EVALUATE THE PHARMACOKINETICS SAFETY TOLERABILITY AND TREATMENT E | 2024 |
| 2024-03-04 | PFIZER INC. | CHILDRENS RESEARCH INSTITUTE | $99,691 | MACHINE LEARNING TO IDENTIFY CHILDREN WITH SICKLE CELL DISEASE AT HIGH RISK FOR RETURN EMERGENCY VISITS AFTER VASOOCCLUS | 2024 |
| 2024-01-05 | Novartis Pharmaceuticals Corporation | Childrens Hospital | $111,058 | An Open-label, Multi-center, Phase IV, Rollover Study for Patients With Sickle Cell Disease Who Have Completed a Prior N | 2024 |
| 2023-05-10 | Novartis Pharmaceuticals Corporation | CHILDRENS HOSPITAL | $146,070 | An Open-label, Multi-center, Phase IV, Rollover Study for Patients With Sickle Cell Disease Who Have Completed a Prior N | 2023 |
| 2023-03-22 | GLOBAL BLOOD THERAPEUTICS, INC. | CHILDRENS RESEARCH INSTITUTE | $1,250 | AN OPENLABEL EXPANDED ACCESS PROTOCOL FOR PEDIATRIC PATIENTS WITH SICKLE CELL DISEASE WHO HAVE NO ALTERNATIVE TREATMENT | 2023 |
| 2023-01-26 | Novartis Pharmaceuticals Corporation | CHILDRENS HOSPITAL | $33 | A phase 2 Multicenter Open Label Study to Assess Appropriate Dosing and to Evaluate Safety of Crizanlizumab with or with | 2023 |
| 2023-01-09 | Novartis Pharmaceuticals Corporation | CHILDRENS HOSPITAL | $272,008 | An Open-label, Multi-center, Phase IV, Rollover Study for Patients With Sickle Cell Disease Who Have Completed a Prior N | 2023 |
| 2023-01-04 | Novartis Pharmaceuticals Corporation | CHILDRENS HOSPITAL | $29,508 | A phase 2 Multicenter Open Label Study to Assess Appropriate Dosing and to Evaluate Safety of Crizanlizumab with or with | 2023 |
| 2022-12-27 | Novartis Pharmaceuticals Corporation | CHILDRENS HOSPITAL | $19,141 | AN OPEN-LABEL, MULTI-CENTER, PHASE IV, ROLLOVER STUDY FOR PATIENTS WITH SICKLE CELL DISEASE WHO HAVE COMPLETED A PRIOR N | 2022 |
| 2022-10-19 | GLOBAL BLOOD THERAPEUTICS, INC. | CHILDRENS NATIONAL MEDICAL CENTER | $1,250 | GBT_GBT_PEDIATRIC_440-007_2926_01 | 2022 |
| 2022-08-23 | GLOBAL BLOOD THERAPEUTICS, INC. | CHILDRENS NATIONAL MEDICAL CENTER | $2,400 | GBT_GBT440-038_3702_01 | 2022 |
| 2022-06-07 | GLOBAL BLOOD THERAPEUTICS, INC. | CHILDRENS NATIONAL MEDICAL CENTER | $4,121 | GLOBA002_GBT440-032_80036131 | 2022 |
| 2022-05-05 | GLOBAL BLOOD THERAPEUTICS, INC. | CHILDRENS NATIONAL MEDICAL CENTER | $4,000 | GLOBA002_GBT440-032_80036131 | 2022 |
| 2022-01-11 | Novartis Pharmaceuticals Corporation | CHILDRENS HOSPITAL | $242,016 | A PHASE 2 MULTICENTER OPEN LABEL STUDY TO ASSESS APPROPRIATE DOSING AND TO EVALUATE SAFETY OF CRIZANLIZUMAB WITH OR WITH | 2022 |
| 2021-12-07 | GLOBAL BLOOD THERAPEUTICS, INC. | CHILDRENS NATIONAL MEDICAL CENTER | $859 | GBT_GBT440-038_3702_01 | 2021 |
| 2021-10-20 | GLOBAL BLOOD THERAPEUTICS, INC. | CHILDRENS NATIONAL MEDICAL CENTER | $4,260 | GBT_GBT440-038_3702_01 | 2021 |
| 2021-06-21 | GLOBAL BLOOD THERAPEUTICS, INC. | CHILDRENS NATIONAL MEDICAL CENTER | $278 | GBT_GBT440-038_3702_01 | 2021 |
| 2021-06-21 | GLOBAL BLOOD THERAPEUTICS, INC. | CHILDRENS NATIONAL MEDICAL CENTER | $2,408 | GBT_GBT440-038_3702_01 | 2021 |
| 2021-05-07 | GLOBAL BLOOD THERAPEUTICS, INC. | CHILDRENS NATIONAL MEDICAL CENTER | $2,408 | GBT_GBT440-038_3702_01 | 2021 |
| 2021-04-19 | GLOBAL BLOOD THERAPEUTICS, INC. | CHILDRENS NATIONAL MEDICAL CENTER | $1,805 | GBT_GBT440-038_3702_01 | 2021 |
| 2021-04-15 | GLOBAL BLOOD THERAPEUTICS, INC. | CHILDRENS RESEARCH INSTITUTE | $16,632 | GBT_GBT_PEDIATRIC_440-007_2926_01 | 2021 |
| 2021-04-15 | GLOBAL BLOOD THERAPEUTICS, INC. | CHILDRENS RESEARCH INSTITUTE | $5,620 | GBT_GBT_PEDIATRIC_440-007_2926_01 | 2021 |
| 2021-04-08 | GLOBAL BLOOD THERAPEUTICS, INC. | CHILDRENS NATIONAL MEDICAL CENTER | $1,704 | GBT_GBT440-038_3702_01 | 2021 |
| 2021-03-10 | GLOBAL BLOOD THERAPEUTICS, INC. | CHILDRENS NATIONAL MEDICAL CENTER | $3,408 | GBT_GBT440-038_3702_01 | 2021 |
| 2021-02-08 | GLOBAL BLOOD THERAPEUTICS, INC. | CHILDRENS RESEARCH INSTITUTE | $2,120 | GBT_GBT_PEDIATRIC_440-007_2926_01 | 2021 |
| 2021-02-05 | GLOBAL BLOOD THERAPEUTICS, INC. | CHILDRENS NATIONAL MEDICAL CENTER | $1,593 | GBT_GBT440-038_3702_01 | 2021 |
| 2021-01-18 | Novartis Pharmaceuticals Corporation | CHILDRENS NATIONAL HEALTH SYSTEM | $389,190 | A PHASE 2 MULTICENTER OPEN LABEL STUDY TO ASSESS APPROPRIATE DOSING AND TO EVALUATE SAFETY OF CRIZANLIZUMAB WITH OR WITH | 2021 |
| 2021-01-06 | GLOBAL BLOOD THERAPEUTICS, INC. | CHILDRENS NATIONAL MEDICAL CENTER | $3,186 | GBT_GBT440-038_3702_01 | 2021 |
| 2020-12-08 | GLOBAL BLOOD THERAPEUTICS, INC. | CHILDRENS NATIONAL MEDICAL CENTER | $13,525 | GBT_GBT440-038_3702_01 | 2020 |
| 2020-10-29 | GLOBAL BLOOD THERAPEUTICS, INC. | CHILDREN'S NATIONAL MEDICAL CENTER - WASHINGTON DC | $8,420 | GBT_GBT_PEDIATRIC_440-007_2926_01 | 2020 |
| 2020-10-02 | GLOBAL BLOOD THERAPEUTICS, INC. | CHILDREN'S NATIONAL MEDICAL CENTER - WASHINGTON DC | $14,118 | GBT_GBT_PEDIATRIC_440-007_2926_01 | 2020 |
| 2020-09-02 | GLOBAL BLOOD THERAPEUTICS, INC. | CHILDRENS RESEARCH INSTITUTE | $1,875 | GBT440-034 | 2020 |
| 2020-09-02 | GLOBAL BLOOD THERAPEUTICS, INC. | CHILDRENS RESEARCH INSTITUTE | $375 | GBT440-034 | 2020 |
| 2020-09-02 | GLOBAL BLOOD THERAPEUTICS, INC. | CHILDRENS RESEARCH INSTITUTE | $1,000 | GBT440-034 | 2020 |
| 2020-09-02 | GLOBAL BLOOD THERAPEUTICS, INC. | CHILDRENS RESEARCH INSTITUTE | $1,250 | GBT440-034 | 2020 |
| 2020-09-02 | GLOBAL BLOOD THERAPEUTICS, INC. | CHILDRENS RESEARCH INSTITUTE | $6,250 | GBT440-034 | 2020 |
| 2020-08-06 | GLOBAL BLOOD THERAPEUTICS, INC. | CHILDRENS RESEARCH INSTITUTE | $2,000 | GBT440-031 | 2020 |
| 2020-08-06 | GLOBAL BLOOD THERAPEUTICS, INC. | CHILDRENS RESEARCH INSTITUTE | $375 | GBT440-031 | 2020 |
| 2020-08-06 | GLOBAL BLOOD THERAPEUTICS, INC. | CHILDRENS RESEARCH INSTITUTE | $1,250 | GBT440-031 | 2020 |
| 2020-07-30 | GLOBAL BLOOD THERAPEUTICS, INC. | CHILDREN'S NATIONAL MEDICAL CENTER - WASHINGTON DC | $8,858 | GBT_GBT_PEDIATRIC_440-007_2926_01 | 2020 |
| 2020-06-19 | GLOBAL BLOOD THERAPEUTICS, INC. | CHILDREN?S RESEARCH INSTITUTE | $15,235 | GBT_GBT_PEDIATRIC_440-007_2926_01 | 2020 |
| 2020-04-14 | Novartis Pharmaceuticals Corporation | CHILDRENS NATIONAL HEALTH SYSTEM | $132,668 | A PHASE 2 MULTICENTER OPEN LABEL STUDY TO ASSESS APPROPRIATE DOSING AND TO EVALUATE SAFETY OF CRIZANLIZUMAB WITH OR WITH | 2020 |
| 2019-06-20 | APO-PHARMA INC. | UNIV OF MI HOSPITALS & HLTH CTRS | $26,762 | LA38-EXT | 2019 |
| 2019-05-24 | Novartis Pharmaceuticals Corporation | CHILDRENS NATIONAL HEALTH SYSTEM | $13,134 | A PHASE 2 MULTICENTER OPEN LABEL STUDY TO ASSESS APPROPRIATE DOSING AND TO EVALUATE SAFETY OF CRIZANLIZUMAB WITH OR WITH | 2019 |
CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.
The area Census
County outline, the place (blue), the tract (orange) and the ZIP center (dot).
In Lanham, MD, county Prince George's County, MD, state Maryland; placed by its city name.
| Measure | Place (city or town) Lanham, MD | County Prince George's County, MD | State Maryland |
|---|---|---|---|
| Population B01003 | 11,433 | 959,754 | 6,206,011 |
| Population, 2020 census P1 | 11,282 | 967,201 | 6,177,224 |
| Median age B01002 | 38.6 | 38.5 | 39.4 |
| Under 18 B01001 | 24.4% | 22.1% | 22.2% |
| 65 and over B01001 | 17.3% | 14.9% | 16.7% |
| Households B11001 | 3,183 | 347,744 | 2,362,928 |
| Foreign born B05002 | 35.0% | 25.3% | 16.6% |
| Median household income B19013 | $103,556 | $101,798 | $103,678 |
| Median family income B19113 | $122,367 | $120,601 | $127,817 |
| Per capita income B19301 | $35,958 | $46,366 | $52,979 |
| Poverty rate B17001 | 7.3% | 10.8% | 9.4% |
| Unemployment rate B23025 | 5.4% | 6.4% | 4.9% |
| Civilian labor force B23025 | 5,952 | 531,986 | 3,313,651 |
| Mean commute (minutes) B08013 | 32.5 | 35.2 | 31.1 |
| Bachelor's degree or higher B15003 | 27.6% | 36.7% | 43.4% |
| Housing units B25001 | 3,405 | 365,506 | 2,560,784 |
| Owner-occupied B25003 | 76.8% | 62.3% | 67.6% |
| Renters B25003 | 23.2% | 37.7% | 32.4% |
| Median home value B25077 | $436,900 | $426,000 | $419,900 |
| Median gross rent B25064 | $2,050 | $1,799 | $1,705 |
| White, not Hispanic B03002 | 4.7% | 10.8% | 46.6% |
| Black B03002 | 52.6% | 58.2% | 28.9% |
| Hispanic or Latino B03002 | 33.7% | 22.5% | 12.5% |
| Asian B03002 | 5.1% | 3.9% | 6.5% |
| American Indian and Alaska Native B03002 | 0.0% | 0.1% | 0.1% |
Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Lanham, MD.
Comments